Label-free impedance detection of cancer cells from whole blood on an integrated centrifugal microfluidic platform.

Authors:
Charles E Nwankire
Charles E Nwankire
Dublin City University
Ireland
Anita Venkatanarayanan
Anita Venkatanarayanan
Biomedical Diagnostics Institute
Thomas Glennon
Thomas Glennon
Biomedical Diagnostics Institute
Tia E Keyes
Tia E Keyes
School of Chemical Sciences
Robert J Forster
Robert J Forster
Dublin City University
Ireland
Dr. Jens Ducree, Dr. rer. nat. habil. Dipl. Phys.
Dr. Jens Ducree, Dr. rer. nat. habil. Dipl. Phys.
Fraunhofer Project Centre at Dublin City University
Professor (Full)
microfluidics, Lab-on-a-Chip, hydrodynanmics, business development, project management, organisational leadership
Glasnevin, Dublin 9 | Ireland

Biosens Bioelectron 2015 Jun 30;68:382-389. Epub 2014 Dec 30.

Biomedical Diagnostics Institute, National Center for Sensor Research, Dublin City University, Ireland; School of Physical Sciences, Dublin City University, Ireland. Electronic address:

An electrochemical Lab-on-a-Disc (eLoaD) platform for the automated quantification of ovarian cancer cells (SKOV3) from whole blood is reported. This centrifugal microfluidic system combines complex sample handling, i.e., blood separation and cancer cell extraction from plasma, with specific capture and sensitive detection using label-free electrochemical impedance. Flow control is facilitated using rotationally actuated valving strategies including siphoning, capillary and centrifugo-pneumatic dissolvable-film (DF) valves. For the detection systems, the thiol-containing amino acid, L-Cysteine, was self-assembled onto smooth gold electrodes and functionalized with anti-EpCAM. By adjusting the concentration of buffer electrolyte, the thickness of the electrical double layer was extended so the interfacial electric field interacts with the bound cells. Significant impedance changes were recorded at 117.2 Hz and 46.5 Hz upon cell capture. Applying AC amplitude of 50 mV at 117.2 Hz and open circuit potential, a minimum of 214 captured cells/mm(2) and 87% capture efficiency could be recorded. The eLoaD platform can perform five different assays in parallel with linear dynamic range between 16,400 and (2.6±0.0003)×10(6) cancer cells/mL of blood, i.e. covering nearly three orders of magnitude. Using the electrode area of 15.3 mm(2) and an SKOV3 cell radius of 5 µm, the lower detection limit is equivalent to a fractional surface coverage of approximately 2%, thus making eLoaD a highly sensitive and efficient prognostic tool that can be developed for clinical settings where ease of handling and minimal sample preparation are paramount.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bios.2014.12.049DOI Listing

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
June 2015
43 Reads
9 PubMed Central Citations(source)
6.41 Impact Factor

Publication Analysis

Top Keywords

centrifugal microfluidic
8
cancer cells
8
eload platform
8
465 cell
4
cell capture
4
capture applying
4
applying amplitude
4
1172 465
4
recorded 1172
4
bound cells
4
cells impedance
4
impedance changes
4
changes recorded
4
amplitude 1172
4
1172 open
4
cells/mm2 87%
4
87% capture
4
capture efficiency
4
efficiency recorded
4
captured cells/mm2
4

Similar Publications